Cognition Therapeutics Announces New Scientific Publication on Therapeutic Potential of Targeting Receptor for
Age-related Degenerative Diseases
Purchases-based Cognition Therapeutics, Inc. announced that a review article titled, “Sigma-2 Receptors – From Basic Biology to Therapeutic Target: A Focus on Age-Related Degenerative Diseases” (doi.org/10.3390/ijms24076251) was published online in the International Journal of Molecular Sciences. This peer-reviewed publication summarizes the current evidence-based understanding of sigma-2 (σ-2) receptor biology and function, and its potential as a therapeutic target for age-related degenerative diseases of the central nervous system, including Alzheimer’s disease, α-synucleinopathies such as dementia with Lewy bodies (DLB), and dry age-related macular degeneration.
This review summarizes the evidence supporting Cognition’s lead σ-2 modulator, CT1812, and provides a strong mechanistic rationale for advancing CT1812 to Phase 2 clinical trials for early- and mild-to-moderate Alzheimer’s disease and DLB as well as an upcoming trial in geographic atrophy secondary to dry AMD.
|